Bharat Immunological & Biological Corporation Ltd

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 26 May 2026, providing investors with the latest insights into its performance and prospects.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 15 May 2026, providing investors with the latest insights into its performance and prospects.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Apr 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 04 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 Apr 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here represent the company’s current position as of 21 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical standing.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 Apr 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 10 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

For the second consecutive session, Bharat Immunological & Biological Corporation Ltd has extended its decline, hitting a fresh 52-week low of Rs 14.62 on 30 Mar 2026. This latest drop comes amid a broader sector underperformance and persistent concerns over the company’s financial health.

Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 30 March 2026, providing investors with an up-to-date view of the company’s performance and outlook.

A sharp decline of 4.29% today dragged Bharat Immunological & Biological Corporation Ltd to a fresh 52-week low of Rs 15.55, extending its downward trajectory despite a brief two-day rally. This fall comes amid a broader market weakness, but the stock’s underperformance is notably more severe than its sector peers.

A sharp decline has pushed Bharat Immunological & Biological Corporation Ltd to a fresh 52-week low of Rs 15.66 on 23 Mar 2026, marking a significant 45.6% drop from its 52-week high of Rs 28.80. This fall comes amid a broader market downturn but is notably more severe than sector and benchmark indices, reflecting company-specific pressures.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics discussed here are based on the company’s current position as of 16 March 2026, providing investors with an up-to-date view of its performance and prospects.

Shares of Bharat Immunological & Biological Corporation Ltd have declined to a fresh 52-week low of Rs.15.8, marking a significant downturn amid ongoing headwinds in the Pharmaceuticals & Biotechnology sector. This new low reflects a continuation of the stock’s subdued performance over the past year, with the company facing multiple financial and market pressures.

Bharat Immunological & Biological Corporation Ltd’s stock declined to a fresh 52-week low of Rs.15.8 today, marking a significant downturn amid ongoing financial headwinds and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 09 April 2024. However, the analysis and financial metrics presented here reflect the company’s current position as of 04 March 2026, providing investors with an up-to-date view of its fundamentals, returns, and market performance.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 February 2026, providing investors with the latest insights into the stock’s performance and outlook.

Bharat Immunological & Biological Corporation Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 09 April 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 10 February 2026, providing investors with the latest insights into its performance and outlook.

Bharat Immunological & Biological Corporation Ltd is rated 'Strong Sell' by MarketsMOJO. This rating was last updated on 09 April 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 30 January 2026, providing investors with the most recent and relevant data to understand the stock’s standing today.

Shares of Bharat Immunological & Biological Corporation Ltd have declined to a fresh 52-week low of Rs.16.76, marking a significant downturn amid broader market pressures and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting ongoing concerns about its financial health and recent performance metrics.

Bharat Immunological & Biological Corporation Ltd’s stock declined to a fresh 52-week low of Rs.16.76 on 20 Jan 2026, marking a significant downturn amid broader market weakness and sectoral pressures. The stock has underperformed its Pharmaceuticals & Biotechnology peers and the benchmark Sensex over the past year, reflecting ongoing financial and performance concerns.